
Gentamicin Sulfate Ophthalmic Solution USP, 0.3% (Sterile)

Rx only

DESCRIPTION

Gentamicin Sulfate Ophthalmic Solution, is a sterile, aqueous solution buffered to approximately pH 7.0 and formulated for ophthalmic use.

EACH mL CONTAINS:

ACTIVE: Gentamicin Sulfate (equivalent to 3 mg gentamicin).


INACTIVES: Dibasic Sodium Phosphate, Sodium Chloride, Monobasic Sodium Phosphate, Purified Water. Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (6.5 - 7.5).

PRESERVATIVE ADDED: Benzalkonium Chloride 0.01%.

Gentamicin is an aminoglycoside antibiotic obtained from cultures of . It is a mixture of the sulfate salts of Gentamicin C , C , C and C . All three components appear to have similar antimicrobial activity. *Micromonospora purpurea*_{121a2a}

Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol.

The structural formula is as follows:



CLINICAL PHARMACOLOGY

Microbiology

Gentamicin sulfate is active against many strains of the following microorganisms: *in vitro*

and Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae,Enterobacter aerogenes Escherichia coli; Haemophilus influenzae, Klebsiella pneumoniae, Neisseriagonorrhoeae, Pseudomonas aeruginosa,Serratia marcescens.

INDICATIONS AND USAGE

Gentamicin sulfate ophthalmic solution is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms:

and Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli; Haemophilus influenzae, Klebsiella pneumoniae, Neisseriagonorrhoeae, Pseudomonas aeruginosa, Serratia marcescens.

CONTRAINDICATIONS

Gentamic in sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

NOT FOR INJECTION INTO THE EYE.

Gentamicin sulfate ophthalmic solution is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

PRECAUTIONS

General

Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible organisms including fungi.

Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician. If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

Information for Patients:

To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

Pregnancy:

Pregnancy Category C. Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

ADVERSE REACTIONS

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

DOSAGE AND ADMINISTRATION

Instill one or two drops into the affected eye(s) every four hours. In severe infections dosage may be increased to as much as two drops every hour.

HOW SUPPLIED

NDC:50436-6752-1 in a BOTTLE, DROPPER of 15 SOLUTION/ DROPSS Store between 2°- 25°C (36°- 77°F). Avoid exposure to excessive heat. **Storage:** KEEP OUT OF REACH OF CHILDREN. Revised: January 2013

Tampa, FL 33637 © Bausch & Lomb Incorporated Bausch & Lomb Incorporated

9116002 9116102 (Folded) (Flat)

GENTAMICIN SULFATE SOLUTION/ DROPS

NDC: 50436-6752-1 GENTAMICIN SULFATE OPHTHALMIC SOLUTION USP,



MFG BY: BAUSCH & LOMB INCORPORATED TAMPA, FL 33637

WARNING: KEEP OUT OF REACH OF CHILDREN. STORE BETWEEN 2-25 ° C (36-77 ° F)CONTROLLED ROOM TEMPERATURE. SEE PACKAGE INSERT FOR DOSAGE INFORMATION. MFG NDC: 24208-580-64 MFG LOT: XXXXXX LOT: XXXXX EXP: XXXXX Pkg by:Unit Dose Services, LLC Dania, FL 33004 NDC: 50435-6752-1 15 ML DRUG: GENTAMICIN SULFATE 0.3 % OPHTHALMIC SOLUTION USP, LOT: XXXXX EXP: XXXXX

NDC: 50436-6752-1 15 ML DRUG: GENTAMICIN SULFATE 0.3 % OPHTHALMIC SOLUTION USP, LOT: XXXXX EXP: XXXXX

NDC: 50436-6752-1 15 ML DRUG: GENTAMICIN SULFATE 0.3 % OPHTHALMIC SOLUTION USP, LOT: XXXXX EXP: XXXXX

NDC: 50436-6752-1 15 ML DRUG: GENTAMICIN SULFATE 0.3 % OPHTHALMIC SOLUTION USP, LOT: XXXXX EXP: XXXXX

GENTAMICIN SULFATE

gentamicin sulfate solution/ drops

0.3 %

15 ML

Product Information							
Product T ype	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:50436-6752(N	DC:24208-580)			
Route of Administration	OPHTHALMIC						
Active Ingredient/Active Moiety							
Ingredient Name			Basis of Strength	Strength			
GENTAMICIN SULFATE (UNII: 8X7386QRLV) (GENTAMICIN - UNII:T6Z9V48IKG)			ENTAMICIN	3 mg in 1 mL			

Inactive Ingredients							
Ingredient Name					Strength		
BENZALKONIUM CHL							
SO DIUM PHO SPHATE,							
HYDRO CHLORIC ACID	HYDRO CHLORIC ACID (UNII: QTT17582CB)						
SO DIUM PHO SPHATE,	SODIUM PHOSPHATE, MONOBASIC (UNII: 3980JIH2SW)						
WATER (UNII: 059QF0K	.O0R)						
SODIUM CHLORIDE (U	NII: 451W47IQ8X)						
SO DIUM HYDRO XIDE (UNII: 55X04QC32I)						
Packaging							
# Item Code	Package Description	Marketing Start Date		Mar	Marketing End Date		
1 NDC:50436-6752-1	15 mL in 1 BOTTLE, DROPPER						
Marketing Information							
Marketing Category	Application Number or Monograph Citation		Marketing Start Date		Iarketing End Date		
ANDA	ANDA064048		05/11/1994				

Labeler - Unit Dose Services (831995316)

Registrant - Unit Dose Services (831995316)

Establishment

Name	Address	ID/FEI	Business Operations
Unit Dose Services		831995316	REPACK(50436-6752)

Revised: 6/2013

Unit Dose Services